Humana (NYSE:HUM) Stock Rating Raised to Outperform at Raymond James Financial

Raymond James Financial upgraded shares of Humana (NYSE:HUM) from a market perform rating to an outperform rating in a research note released on Monday, Marketbeat Ratings reports. The firm currently has $520.00 price target on the insurance provider’s stock.

Several other brokerages also recently commented on HUM. Weiss Ratings upgraded shares of Humana from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, August 14th. Oppenheimer increased their price objective on shares of Humana from $405.00 to $475.00 and gave the stock an “outperform” rating in a research report on Friday. Royal Bank Of Canada raised their price objective on shares of Humana from $246.00 to $415.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 9th. Morgan Stanley upgraded Humana from an “underweight” rating to an “overweight” rating in a research report on Friday. Finally, Lake Street Capital assumed coverage on Humana in a research note on Thursday, July 30th. They set a “buy” rating on the stock. Twenty-one research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $448.74.

Humana Stock Up 0.1%

NYSE HUM opened at $432.24 on Monday. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. The company has a fifty day moving average of $389.75 and a two-hundred day moving average of $336.54. The firm has a market capitalization of $51.90 billion, a price-to-earnings ratio of 40.89, a PEG ratio of 2.67 and a beta of 0.74. Humana has a 52 week low of $163.11 and a 52 week high of $456.50.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, beating analysts’ consensus estimates of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The business had revenue of $40.89 billion for the quarter, compared to analysts’ expectations of $40.58 billion. During the same quarter in the previous year, the business posted $6.27 earnings per share. The business’s revenue was up 26.2% compared to the same quarter last year. On average, analysts predict that Humana will post 9.00 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 27th. Stockholders of record on Friday, October 30th will be given a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Friday, October 30th. Humana’s dividend payout ratio (DPR) is 33.49%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Chapin Davis Inc. purchased a new position in Humana in the 3rd quarter worth about $12,323,000. GAMMA Investing LLC lifted its holdings in Humana by 27.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,996 shares of the insurance provider’s stock valued at $762,000 after buying an additional 429 shares in the last quarter. Gradient Investments LLC boosted its position in Humana by 2.5% in the 3rd quarter. Gradient Investments LLC now owns 13,738 shares of the insurance provider’s stock valued at $5,242,000 after buying an additional 330 shares during the period. Valeo Financial Advisors LLC boosted its position in Humana by 15.3% in the 3rd quarter. Valeo Financial Advisors LLC now owns 814 shares of the insurance provider’s stock valued at $310,000 after buying an additional 108 shares during the period. Finally, Vista Investment Partners LLC purchased a new stake in Humana in the 3rd quarter valued at about $3,254,000. 92.38% of the stock is currently owned by institutional investors.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana reported that 95% of its Medicare Advantage members are enrolled in plans rated four stars or higher for 2027. The improvement could support higher quality-bonus payments in 2028, enhance benefits and improve the company’s competitive position. Humana Hits 95% Four-Star Coverage: What it Means for HUM
• Positive Sentiment: Raymond James upgraded HUM from “market perform” to “outperform” and set a $520 price target, implying roughly 20% upside from the referenced price. Robert W. Baird also upgraded the stock, adding to the bullish analyst momentum. Humana Raised to Outperform at Raymond James Financial
• Neutral Sentiment: Humana will release third-quarter 2026 results and 2026 guidance on November 6, followed by a management question-and-answer session. The report could provide confirmation—or challenge—to the recent rally and analysts’ earnings expectations. Humana to Release Third Quarter 2026 Results
• Neutral Sentiment: DataMeds AI’s Helomics ChemoFx cancer assay was added to Humana’s Medicaid coverage policy for certain gynecologic cancers. The move may expand access to testing and reimbursement, but the direct financial effect on Humana is likely limited. DataMeds AI Stock Rises After Humana Adds Medicaid Coverage
• Negative Sentiment: Analysts and market commentary have cautioned that Humana’s valuation may already reflect much of the star-rating recovery. With a referenced P/E ratio near 41, further gains may depend on earnings growth and successful execution. Humana’s Star Ratings Progress Doesn’t Erase Valuation Concerns

Humana Company Profile

Humana Inc is a health and well-being company headquartered in Louisville, Kentucky. Founded in 1961, the company began as a nursing home operator before expanding into hospitals and health insurance. Today, Humana primarily provides health insurance products and healthcare services for older adults, individuals, military families and other members in the United States.

Humana’s insurance business offers Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid coverage in select markets.